• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Intratect 50 g/l
    / Kamada

    Active Ingredient

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    1 g / 20 ml

    partial basket chart 4131 9455


    2.5 g / 50 ml

    partial basket chart 5395 9459


    5 g / 100 ml

    partial basket chart 4132 9456


    10 g / 200 ml

    partial basket chart 4134 9457


    The dose and dose regimen is dependent on the indication.
    In replacement therapy the dose may need to be individualised for each patient dependent on the pharmacokinetic and clinical response. The following dose regimens are given as a guideline.
    Replacement therapy in primary immunodeficiency syndromes: The dose regimen should achieve a trough level of IgG (measured before the next infusion) of at least 5 to 6 g/l. Three to six months are required after the initiation of therapy for equilibration to occur. The recommended starting dose is 8-16 ml (0.4-0.8 g)/kg given once, followed by at least 4 ml (0.2 g)/kg given
    every three to four weeks. The dose required to achieve a trough level of 5-6 g/l is of the order of 4-16 ml (0.2-0.8 g)/kg/month. The dosage interval when steady state has been reached varies from 3-4 weeks.
    Trough levels should be measured and assessed in conjunction with the incidence of infection. To reduce the rate of infection, it may be necessary to increase the dosage and aim for higher trough levels.
    Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed; hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation; congenital AIDS with recurrent bacterial infections: The recommended dose is 4-8 ml (0.2-0.4 g)/kg every three to four weeks.
    Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation: The recommended dose is 4-8 ml (0.2-0.4 g)/kg every three to four weeks. The trough levels should be maintained above 5 g/l.
    Primary immune thrombocytopenia: There are two alternative treatment schedules:
    – 16-20 ml (0.8-1 g)/kg given on day one, this dose may be repeated once within 3 days.
    – 8 ml (0.4 g)/kg given daily for two to five days.
    The treatment can be repeated if relapse occurs.
    Guillain Barré syndrome: 8 ml (0.4 g)/kg/day over 5 days.
    Kawasaki disease: 32-40 ml (1.6-2.0 g)/kg should be administered in divided doses over two to five days or 40 ml (2.0 g)/kg as a single dose. Patients should receive concomitant treatment with acetylsalicylic acid.
    The dosage recommendations are summarised in table 1 at the attached doctor’s leaflet.
    Paediatric population: The posology in children and adolescents (0-18 years) is not different to that of adults as the posology for each indication is given by body weight and adjusted to the clinical outcome of the above mentioned
    Method of administration: For intravenous use. Intratect should be infused intravenously at an initial rate of not more than 1.4 ml/kg/h for 30 minutes.
    If well tolerated, the rate of administration may gradually be increased to a maximum of 1.9 ml/kg/h for the remainder of the infusion.
    See prescribing information for full details.


    Replacement therapy in adults, and children and adolescents (0-18 years) in:
    – Primary immunodeficiency syndromes with impaired antibody production.
    – Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed.
    – Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation.
    – Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT).
    – Congenital AIDS with recurrent bacterial infections.
    Immunomodulation in adults, and children and adolescents (0-18 years) in:
    – Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count.
    – Guillain Barré syndrome.
    – Kawasaki disease.


    Hypersensitivity to the active substance (human immunoglobulins) or to any of the excipients.
    Patients with selective IgA deficiency who developed antibodies to IgA, as administering an IgAcontaining product can result in anaphylaxis.

    Special Precautions

    Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
    Precautions for use: Potential complications can often be avoided by ensuring that patients:
    • are not sensitive to human normal immunoglobulin by initially injecting the product slowly (1.4 ml/kg/h corresponding to 0.023 ml/kg/min),
    • are carefully monitored for any symptoms throughout the infusion period. In particular, patients naive to human normal immunoglobulin, patients switched from an alternative IVIg product or when there has been a long interval since the previous infusion should be monitored at the hospital during the first infusion and for the first hour after the first infusion, in order to detect potential adverse signs. All other patients should be observed for at least 20 minutes after administration.
    In all patients, IVIg administration requires:
    • adequate hydration prior to the initiation of the infusion of IVIg
    • monitoring of urine output
    • monitoring of serum creatinine levels
    • avoidance of concomitant use of loop diuretics
    In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped. The treatment required depends on the nature and severity of the adverse reaction.
    Infusion reaction: Certain adverse reactions (e.g. headache, flushing, chills, myalgia, wheezing, tachycardia, lower back pain, nausea, and hypotension) may be related to the rate of infusion. The recommended infusion rate given under section 4.2 at the attached doctor’s leaflet must be closely followed. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period.
    Adverse reactions may occur more frequently
    • in patients who receive human normal immunoglobulin for the first time or, in rare cases, when the human normal immunoglobulin product is switched or when there has been a long interval since the previous infusion
    • in patients with an untreated infection or underlying chronic inflammation
    Hypersensitivity: Hypersensitivity reactions are rare.
    Anaphylaxis can develop in patients
    • with undetectable IgA who have anti-IgA antibodies
    • who had tolerated previous treatment with human normal immunoglobulin
    In case of shock, standard medical treatment for shock should be implemented.
    See prescribing information for full details.

    Side Effects

    Adverse reactions caused by human normal immunoglobulins (in decreasing frequency) encompass:
    – chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain.
    – reversible haemolytic reactions; especially in those patients with blood groups A, B, and AB and (rarely) haemolytic anaemia requiring transfusion.
    – (rarely) a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.
    – (rarely) transient cutaneous reactions (including cutaneous lupus erythematosus – frequency unknown).
    – (very rarely) thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism, deep vein thromboses.
    – cases of reversible aseptic meningitis.
    – cases of increased serum creatinine level and/or occurrence of acute renal failure.
    – cases of Transfusion Related Acute Lung Injury (TRALI).
    See prescribing information for full details.

    Drug interactions

    Live attenuated virus vaccines: Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella. After administration of this medicinal product, an interval of 3 months should elapse before vaccination with  live attenuated virus vaccines. In the case of measles, this impairment may persist for up to 1 year.
    Therefore patients receiving measles vaccine should have their antibody status checked.
    Loop diuretics: Avoidance of concomitant use of loop diuretics.
    Paediatric population: It is expected that the same interaction mentioned for the adults may also occur in the paediatric population.

    Pregnancy and Lactation

    Pregnancy: The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. IVIg products have been shown to cross the placenta, increasingly during the third trimester.
    Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are expected.
    Lactation: Immunoglobulins are excreted into human milk. No negative effects on the breastfed newborns/infants are anticipated.


    Overdose may lead to fluid overload and hyperviscosity, particularly in patients at risk, including elderly patients or patients with cardiac or renal impairment.

    Important notes

    Incompatibilities: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products, or with any other IVIg products.
    Shelf life: After first opening, an immediate use is recommended.
    Storage: Do not store above 25°C. Do not freeze.

    Biotest AG
    Licence holder